Barely a week after announcing it was moving into a new corporate headquarters, Sangamo announced it has dosed the first patient in its Phase I/II gene therapy trial. Source: BioSpace
The $49M in Series A funding will be used to develop the company's enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the…
The transaction is expected to close by the end of Cardinal Health's fiscal year, subject to closing conditions and regulatory clearances. Source: BioSpace
Denali plans to make a $100M IPO under the symbol DNLI. Source: BioSpace
Alex Azar was head of U.S. operations for Lilly until January. Source: BioSpace
It's not always easy to see when a company is a "disruptor," which is to say, that it causes a paradigm shift in how an industry operates. Source: BioSpace
The cash will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene. Source: BioSpace
The new space is located just a few miles from Kendall Square that has become the hub of the Boston biotech industry. Source: BioSpace
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS. Source: BioSpace
Two days after Mylan CEO Heather Bresch said she sees a "strong finish" for the company through the rest of 2017, the company has reportedly let between 200 and 300…